Compare · CDIO vs IDXX
CDIO vs IDXX
Side-by-side comparison of Cardio Diagnostics Holdings Inc. (CDIO) and IDEXX Laboratories Inc. (IDXX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CDIO and IDXX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- IDXX is the larger of the two at $44.27B, about 7516.4x CDIO ($5.9M).
- Over the past year, CDIO is down 58.9% and IDXX is up 8.1% - IDXX leads by 67.0 points.
- IDXX has been more active in the news (5 items in the past 4 weeks vs 2 for CDIO).
- IDXX has more recent analyst coverage (23 ratings vs 0 for CDIO).
- Company
- Cardio Diagnostics Holdings Inc.
- IDEXX Laboratories Inc.
- Price
- $1.96-0.51%
- $561.97-0.07%
- Market cap
- $5.9M
- $44.27B
- 1M return
- +7.69%
- -1.85%
- 1Y return
- -58.91%
- +8.09%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- 1991
- News (4w)
- 2
- 5
- Recent ratings
- 0
- 23
IDEXX Laboratories Inc.
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Latest CDIO
- Cardio Diagnostics Holdings, Inc. to Showcase Precision Cardiovascular Solutions at Four National Benefits Conferences in June
- IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Meesha Dogan, CEO of Cardio Diagnostics Holdings Inc.
- SEC Form 10-Q filed by Cardio Diagnostics Holdings Inc.
- IBN Initiates Coverage of Cardio Diagnostics Holdings Inc.
- SEC Form 4 filed by Fung Peter K
- SEC Form 4 filed by Betts Wendy J
- SEC Form 4 filed by Intrater James
- SEC Form 4 filed by Burton Paul Frederick
- SEC Form 10-K filed by Cardio Diagnostics Holdings Inc.
- Cardio Diagnostics Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
Latest IDXX
- Executive Vice President Fennell George converted options into 639 shares and covered exercise/tax liability with 284 shares, increasing direct ownership by 4% to 10,433 units (SEC Form 4)
- SEC Form SD filed by IDEXX Laboratories Inc.
- IDEXX Expands Fecal Dx Antigen Testing Platform with Taeniid Tapeworm Detection
- IDEXX SDMA Now Integrated into the Most Common Catalyst Chemistry Profiles
- The Biology Came First.
- IDEXX Laboratories Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form 4 filed by Director Samad Sam
- SEC Form 4 filed by Director Vandebroek Sophie V.
- SEC Form 4 filed by Director Peacock Karen
- SEC Form 4 filed by Director Junius Daniel M